PL3100
PL-NAP-002
Phase 2 small_molecule completed
Quick answer
PL3100 for Gastroduodenal Ulcerations is a Phase 2 program (small_molecule) at Protalix BioTherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Protalix BioTherapeutics
- Indication
- Gastroduodenal Ulcerations
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed